Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of Bersacapavir in Healthy Subjects and Patients with Chronic Hepatitis B
NCT02662712Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, randomised, double-blind trial of bersacapavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, Number of Participants With Abnormal Physical Examinations and 5 more. Started Dec 2015; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02662712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662712.